SyneuRx is a clinical-stage biotech with eight late-phase programs spanning several CNS conditions, including depression, dementia, and schizophrenia. Our company leads in NMDA receptor modulation, a promising platform to deliver multiple first-in-class assets across CNS and antiviral markets.